Content
Search
Navigation
Sitemap
About
View this section
View this section
Who we are
Our NAV Growth Framework
Our purpose, culture and values
Our people
View this section
View this section
Board of Directors
Portfolio
View this section
View this section
Portfolio data
Late-stage clinical companies
Overview
Autolus Therapeutics
Beacon Therapeutics
Clinical companies
Overview
iOnctura
Spur Therapeutics
Quell Therapeutics
Anaveon
Pre-clinical companies
Overview
Resolution Therapeutics
Purespring Therapeutics
Forcefield Therapeutics
OMass Therapeutics
Mosaic Therapeutics
Kesmalea Therapeutics
Yellowstone Biosciences
Slingshot Therapeutics
Previous portfolio companies
Overview
Gyroscope Therapeutics
Blue Earth
Nightstar
Neogene Therapeutics
14MG
Azeria Therapeutics
Clade Therapeutics
Sustainability
View this section
View this section
Our approach to sustainability reporting
Sustainability policies
The Foundation
News & insights
View this section
View this section
News
Insights & articles
Publications & presentations
Investors
View this section
View this section
Results and presentations
RNS and inside information
Share price centre
Governance
Our Committees
Financial calendar
Events calendar
Analysts and advisers
Shareholder information
Overview
Regulatory publications
Shareholder documents
FAQs
Contact
News & insights
Insights & articles
Syncona FY20: Martin Murphy discusses the impact of COVID-19
Back to News & insights
Related Insights and articles
24.03.23
Leveraging the Syncona team for our next phase of growth
World class leadership
Syncona
01.03.23
Good science must survive in challenging markets
World class leadership
Syncona
11.06.20
Syncona FY20: Martin Murphy discusses the outlook for Syncona
Syncona
Close menu
About
View this section
View this section
Who we are
Our NAV Growth Framework
Our purpose, culture and values
Our people
View this section
View this section
Board of Directors
Portfolio
View this section
View this section
Portfolio data
Late-stage clinical companies
Overview
Autolus Therapeutics
Beacon Therapeutics
Clinical companies
Overview
iOnctura
Spur Therapeutics
Quell Therapeutics
Anaveon
Pre-clinical companies
Overview
Resolution Therapeutics
Purespring Therapeutics
Forcefield Therapeutics
OMass Therapeutics
Mosaic Therapeutics
Kesmalea Therapeutics
Yellowstone Biosciences
Slingshot Therapeutics
Previous portfolio companies
Overview
Gyroscope Therapeutics
Blue Earth
Nightstar
Neogene Therapeutics
14MG
Azeria Therapeutics
Clade Therapeutics
Sustainability
View this section
View this section
Our approach to sustainability reporting
Sustainability policies
The Foundation
News & insights
View this section
View this section
News
Insights & articles
Publications & presentations
Investors
View this section
View this section
Results and presentations
RNS and inside information
Share price centre
Governance
Our Committees
Financial calendar
Events calendar
Analysts and advisers
Shareholder information
Overview
Regulatory publications
Shareholder documents
FAQs
Contact
Search
Search